The Effect of Oseltamivir on the Disease Progression of Lethal Influenza A Virus Infection: Plasma Cytokine and miRNA Responses in a Mouse Model

Figure 1

Prophylactic oseltamivir treatment delay severity of lethal influenza infection progression in mice. Body temperature ((a), (b), and (c)), weight loss ((d), (e), and (f)), and survival ((g), (h), and (i)) of Balb/c mice infected with mouse adapted A/Puerto Rico/8/34 (H1N1) virus and treated with oseltamivir phosphate. For the prophylactic group ((a), (d), and (g)), groups of 40 mice were infected with 1000 TCID50 virus and treated 2 h before infection with oseltamivir. The therapeutic groups were infected with 1000 TCID50 ((b), (e), and (h)) or 100 TCID50 ((c), (f), and (i)) virus and treated 24 h after infection. Prophylactic and therapeutic groups () were administered with oseltamivir 10 mg/kg by oral gavage twice daily for 5 days. An infected group () gavaged with distilled water was added as control for each experiment. To ascertain significance, two tailed and two sample unequal variances Student’s -test was used (. The Kaplan-Meier method was used to estimate the probability of survival.